Cellphire, Inc. announced today that it had closed a $3,000,000.00 funding round, with investments from both new investors and existing investors, management, and the board of directors.
"The additional capital will augment the $69 million commitment from BARDA [The Biomedical Advanced Research and Development Authority]," said CEO Stephen Willard. "It also enables us to initiate the commercial launch of our Veterinary subsidiary BodeVet, Inc."
BodeVet is expected to introduce its first commercial product, a freeze-dried canine platelet-derived hemostatic agent branded StablePlate RX(TM), at the International Veterinary Emergency and Critical Care Symposium in September 2017.
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com